BACKGROUND Point-by-point catheter ablation is an established treatment for drug-refractory paroxysmal atrial
P oint-by-point catheter ablation is an established treatment for drugrefractory paroxysmal atrial fibrillation (PAF) (1, 2) . However, it is time consuming, requires excellent technique to achieve complete pulmonary vein (PV) isolation, and is associated with severe complications (1) (2) (3) (4) . An ideal catheter ablation method to treat atrial fibrillation (AF) would be quicker, less technically difficult, minimize collateral damage, and provide durable PV isolation. A radiofrequency HotBalloon catheter (Central Illustration) has been developed to overcome several of these limitations (5, 6) . The balloon membrane material is elastic and compliant, so it fits the variable PV anatomy (7) . Consequently, this clinical study was undertaken to evaluate if novel HotBalloon ablation (HBA) was safe and effective compared with antiarrhythmic drug therapy (ADT) for the treatment of PAF.
METHODS
This study was conducted as a prospective multicenter randomized study of patients with drug-refractory (resistant and/or intolerant to) symptomatic PAF comparing treatment with HBA or ADT at 17 sites in Japan. Written informed consent was obtained from all patients. This study protocol was in accord with the Japanese good clinical practice guidance for medical devices and approved by the institutional review board at each site that participated in this study. 
HotBalloon Ablation vs. Antiarrhythmic Drug Therapy laboratory for analysis. Adverse events were adjudicated by the investigator at each site, and were assessed by an independent evaluation committee.
The AADs were determined by the investigator using Japanese antiarrhythmic guidelines.
HOTBALLOON ABLATION GROUP. The SATAKE HotBalloon ablation system (Toray Industries, Inc., Tokyo, Japan) was composed of a 13-F balloon catheter, an inner diameter 13- Q u a l i t y o f l i f e . Quality of life was investigated at baseline and at the end of this study (or at study discontinuation) using the 36-item Short-Form Health Survey Version 2 Japan (SF-36v2).
S a f e t y e n d p o i n t s . Serious adverse events (SAEs)
and major complications (MJCs) were investigated. and an intergroup comparison was conducted using a log-rank test. We used Cox's proportional hazard model to estimate the hazard ratio and its Wald-type 95% confidence interval (CI). Events that had occurred during the blanking period and termination were treated as those occurring at the first day of the evaluation period (day 0). Patients were randomized to HBA group or ADT group. Thirty-four of 40 patients who completed participation in the ADT group continued to the crossover group (see Methods). ADT ¼ antiarrhythmic drug therapy; HBA ¼ HotBalloon ablation.
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For the SF-36v2, analysis of covariance was performed using changes from baseline at the end of this study or study discontinuation, with the baseline as a covariate. SAS version 9.3 software (SAS Institute Inc., Cary, North Carolina) was used.
RESULTS
PATIENT CHARACTERISTICS. A total of 153 patients were enrolled, with 104 and 49 patients randomized to the HBA group and the ADT group, respectively. Baseline characteristics in the HBA group were similar to those in the ADT group ( Table 1) . The mean CHADS 2 (congestive heart failure, hypertension, age 75 or older, diabetes, and stroke scale) score was <1 in both groups, indicating that patients with a low risk of embolism were enrolled.
PROCEDURAL CHARACTERISTICS. Procedural characteristics are shown in Table 2 . Values are % or mean AE SD. *From the time of transseptal puncture to the time of protamine administration after ablation. †The sum of ablation time for each PV.
HBA ¼ HotBalloon ablation; PV ¼ pulmonary vein. SAFETY OUTCOMES. Adverse events were assessed by the investigators and the independent evaluation committee. There were no differences in assessment results, other than for 1 event of cerebral infarction.
For 1 event of cerebral infarction, the independent evaluation committee considered that the causal relationship with HotBalloon could not be completely ruled out, whereas the investigator did not consider it to be related.
M J C s . The incidence of MJCs in all patients
undergoing HBA was 11.2% (95% CI: 6.4 to 17.8; 15 patients, 17 events) ( Table 5 ). There was no esophageal perforation, cardiac tamponade, cerebral infarction which was classified as category 2 of MJC, or PV stenosis which was classified as category 3 of MJC. P h r e n i c n e r v e i n j u r y . The incidence of phrenic nerve paralysis was 3.7% (5 of 134). The events in the 5 patients were recovered within 9 to 13 months, and inpatient hospitalization or prolongation of existing hospitalization was not needed. A d v e r s e e v e n t s . There was no occurrence of heart wall perforation, cardiac tamponade, injury of a coronary artery, valve, or chordae tendineae, atrialesophageal fistula, or esophageal perforation. The incidence of adverse events related to vascular access sites whose causal relationship with the HotBalloon catheter could not be ruled out was 20.9% (28 of 134 patients); however, none of the events was reported to be SAEs, and none required surgical treatment or blood transfusion.
DISCUSSION
The main finding of this study is the demonstration of the superiority of HBA compared with ADT in the treatment of patients with PAF refractory to AADs. Outcomes were achieved without using "touch-up" ablation using a conventional ablation catheter.
Abbreviations as in Tables 1 and 2 .
Several studies involving other ablation therapies for AF have reported significant adverse events such as PV stenosis requiring intervention, atrial-esophageal fistula, permanent phrenic nerve paralysis, pyloric spasm, and death (1, 4) . None of the patients in this study experienced these serious events. ANTIARRHYTHMIC DRUG THERAPY. The chronic success rate in the ADT group was 4.7% in this study.
The event rate by Kaplan-Meier method was 7.3% in STOP AF trial (13); 8.3% in this study; and 16.0% in Thermocool AF trial (11). These results were similar. HotBalloon Ablation vs. Antiarrhythmic Drug Therapy
In the case of a similar study design, the effectiveness of AADs therapy in drug-refractory symptomatic PAF patients has been reported to typically result in a 5% to 20% chronic effectiveness success rate.
QUALITY OF LIFE. The SF-36v2 form, a comprehensive quality of life scale not limited to some diseases (14) , has been widely used to evaluate symptom change and symptomatic arrhythmia burden as an AF ablation outcome. In this study, many items for patients in the HBA group improved significantly compared to their baseline values and the values of the ADT group ( Table 4 ), suggesting that HBA may not only provide rhythm control but also decrease symptoms and improve physical and mental health.
COMPLIANT BALLOON FITS VARIATIONS IN PV
ANATOMY. The HotBalloon material is compliant enough to accommodate variations in PV anatomy. As previously reported, compliance of the balloon membrane also allows the device to be used to perform a box isolation procedure for the treatment of various types of AF (7).
The temperature of the fluid in the HotBalloon during radiofrequency energy delivery is not susceptible to the effects of the temperature of the circulating blood in the surrounding vessel. Values are % (number of events). *Total MJCs rate means the number of patients experiencing MJC.
MJCs ¼ major complications; other abbreviations as in Tables 1 and 2 . The authors thought that these 2 events were important "procedure-related SAE" as both of the incidents occurred within 24 h after the procedure.
Although both events were fully resolved 2 and 27 days after the procedure, respectively, careful attention must be paid to the proper use of HotBalloon and other devices, with proper care of puncture sites and anticoagulation treatment.
STUDY LIMITATIONS. Although this trial was a prospective multicenter randomized study, there were several limitations to be considered. The evaluation period was 48 weeks. A longer period trial should be conducted in the future to investigate the effectiveness and safety of the thermal properties of HBA.
There were no devices in widespread use that were approved for PAF treatment in Japan at the time (2011) of planning this study, so HBA was not comparable with other ablation devices as controls.
In addition, the definitions of recurrence of AF and of the chronic success were different in the trials for HotBalloon Ablation vs. Antiarrhythmic Drug Therapy D E C E M B E R 2 7 , 2 0 1 6 : 2 7 4 7 -5 7
other ablation devices. The effectiveness of HBA showed superiority to ADT, but it was difficult to simply compare the HBA with other ablation devices.
In this trial, no routine esophageal endoscopy was performed to investigate esophageal injury. In addition, the interpretation of the quality-of-life data is limited due to the high crossover rate. 
CONCLUSIONS

